Mainz, 2017-10-25 – TRON scientific advisor Prof. Dr. Dr. Cornelis J. Melief, Leiden, Netherlands, will be awarded with the degree of an honorary medical doctor. Melief will be awarded for his lifetime achievements as a pioneer of tumor immunology, as well as for his commitment and deserts regarding immunological research in Mainz. Further information about
Author Archive | thomas
Was versprechen neuartige personalisierte Krebsimmuntherapien? Wie können Patienten von Ihnen profitieren, und welche Risiken bergen die Behandlungen? Zwei neue Ansätze in der Krebsimmuntherapie sind die CAR-T-Methode und die so genannten Neoantigen-Vakzine. Beide werden gerade getestet und sind sehr vielversprechend. Der regionale Radiosender SWR2 sendete hierzu einen Radiobeitrag in seinem Programm. Einen Mitschnitt sowie ein Transkript
Among nucleic acid-based delivery platforms, self-amplifying RNA (saRNA) vectors are of increasing interest for applications such as transient expression of recombinant proteins and vaccination. Although saRNA is a promising technology, antigen expression from saRNA is limited by the host cells’ innate interferon response. TRON’s Tim Beissert and colleagues show, in an upcoming issue of Human
Mainz, September 6, 2017 – Individualized cancer immunotherapy Prof. Ugur Sahin, Managing Director (Science and Research) and Co-Founder of TRON, will talk at the Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in our hometown Mainz. His talk is titled “Individualized Cancer Immunotherapy – Exploring a new landscape” and will cover the implementation of an RNA-based approach
Mainz, September 2017 – TRON will also participate at the THIRD CRI-CIMT-EATI-AACR INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE in Mainz this year. Meet and talk to our experts in: Bioinformatics: Wednesday, 12:30-2:00 pm Next Generation Sequencing: Wednesday, 3:00-4:00 pm Biomarker: Thursday, 11:30-1:00 pm Immunomonitoring: Thursday, 3:00-4:00 pm Pre-Clinical Research: Friday, 12:30-2:00 pm T-cell Vaccines & Immunotherapy: Friday,
Mainz, July 5th 2017 – Today, TRON and BioNTech AG announced the publication of Phase I clinical trial results in the renowned journal Nature.
Mainz, June 2017 – We are pleased to announce that our close cooperation partner BioNTech has today published an article in Nature Medicine. The paper entitled “Elimination of large tumors in mice by mRNA-encoded bispecific antibodies” reports preclinical data featuring their novel class of mRNA-encoded antibody drugs called RiboMABs® and describes the application of their